Amphastar Pharmaceuticals, Inc. /
Eli Lilly and Company
Amphastar completes BAQSIMI acquisition from Eli Lilly and Company
- Price
- $500m
- Stage
- Closed
What happened
Amphastar Pharmaceuticals, Inc. completed its acquisition of Eli Lilly and Company’s BAQSIMI business and related assets on June 30, 2023.
Amphastar paid $500 million at closing and is required to pay an additional $125 million at the one-year anniversary. Terms also include potential milestone payments of up to $450 million.
The source
Everything on this page comes from the source below.
Amphastar completes BAQSIMI acquisition from Eli Lilly and Company
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly